BioCryst rallies on gout study; indices diverge – MarketWatch
By Dr. Matthew Watson
 HealthNewsDigest.com | BioCryst rallies on gout study; indices diverge MarketWatch The NYSE Arca Pharmaceutical Index (INDEX:DRG) was down marginally at 293.68 while the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.6% to 1178.34. BioCryst Reports Positive Results from Part One of Its Phase 2a Study of ...MarketWatch (press release) BioCryst says gout drug shows positive resultsReuters |
Uncategorized
Comments Off on BioCryst rallies on gout study; indices diverge – MarketWatch |
April 29th, 2010
This author published 5912 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research